NeoMTA2
Phase 2Small molecule
NeoMTA2 is one of 28 small molecule programs targeting AIN. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in AIN
#DrugCompanyPhaseTrials
1Lynparza
AstraZenecaPhase 2
Avastin
RochePhase 2
Plaquenil
Jazz PharmaceuticalsPhase 2
Reblozyl
Bristol-Myers SquibbPhase 2
Jevtana
SanofiPhase 2
GM-CSF
YY-mAbs Therapeutics
Phase 3
Paraplatin
AAvyxa
Phase 2
Brukinsa
BBeOne Medicines
Phase 2
Vepesid
AAvyxa
Phase 2
Rayos
RRoxane Laboratories
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
AIN1 trial
Clinical and Radio-graphic Evaluation of Non-staining Bio-active Bio-ceramic (Neo MTA 2) in Revascularization
Not yet recruiting·—·Phase 2·NCT06637761·22 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NeoMTA2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCairo University